It is in this context that arsenic trioxide treatment of mutant p53 cancer cells is interesting, because although the drug has been demonstrated to target mutant p53 for proteasomal degradation (Yan et al., 2011), the activity against PML in this context has yet to be demonstrated, and neither has the consequence for cell viability. The gene discussed is TP53; the disease is cancer.